Comparison of survival between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy followed by surgery for esophageal squamous cell carcinoma
10.3760/cma.j.issn.1004-4221.2019.12.003
- VernacularTitle: 胸段食管鳞癌不同新辅助治疗模式联合手术的生存分析
- Author:
Chengcheng FAN
1
;
Zhuo FENG
;
Hong GE
;
Ke YE
;
Hao WANG
;
Xiaoli ZHENG
;
Yougai ZHANG
;
Shuai SONG
;
Peizan NI
;
Ruiyun ZHANG
;
Hui LUO
Author Information
1. Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasm/neoadjuvant radiotherapy;
Esophageal neoplasm/neoadjuvant chemotherapy;
Prognosis
- From:
Chinese Journal of Radiation Oncology
2019;28(12):890-895
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the effect of neoadjuvant chemoradiotherapy (NCRT) and neoadjuvant chemotherapy (NCT) on the survival of patients with esophageal cancer.
Methods:Clinical data of 275 cases of thoracic esophageal squamous cell carcinoma treated with neoadjuvant therapy combined with surgery from December 2011 to December 2015 were analyzed retrospectively. The data of treatment and follow-up were complete and analyzable. There were 70 cases in the NCRT group and 205 cases in the NCT group. The survival rate was calculated by Kaplan-Meier method and statistically compared by log-rank test, and multivariate analysis was performed by Cox regression model.
Results:The median follow-up time was 32(3-84) months. The median survival time and recurrence-free survival time was 42(3-84) months and 30(3-84) months, respectively. The overall 3-and 5-year survival rates were 56.8% and 45.9%, respectively, and the 3-and 5-year recurrence-free survival rates were 45.1% and 38.9%, respectively. The median survival time in the NCRT and NCT groups was 46(7-84) and 40(4-74) months, and the median recurrence-free survival time was 31(3-84) and 28(3-69) months, respectively. The 3-and 5-year overall survival of the two groups were 59.1%, 47.1% and 56.3%, 47.5%(P=0.515), and the 3-and 5-year recurrence-free survival were 44.5%, 40.1% and 47%, 39%, respectively. There was no significant difference in the survival between two neoadjuvant therapy modes (P=0.554). Multivariate analysis showed that postoperative pathological TNM staging was an independent factor affecting the prognosis of patients with esophageal cancer (P=0.001).
Conclusions:The survival results of NCRT are similar to those of NCT. Postoperative pathological staging is an independent survival factor.
